Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the biphenyl and pyrimidinediamine chemical classes. It is an experimental dihydrofolate reductase (DHFR) inhibitor with potent activity in vitro. The compound has demonstrated nanomolar inhibitory activity against Candida albicans DHFR, suggesting potential as an antifungal agent or as a lead structure for further development of DHFR-targeted therapies. There are no approved indications or clinical use reported; it remains at the preclinical/experimental stage[2][9][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-[(3R)-3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine.